Healthcare Nov 02, 2021 05:02 PM (GMT+8)
EU billion health learned on the 2nd that recently, the artificial intelligence new drug R & D enterprise "Yuanyi wisdom ainnocence" announced that it had obtained tens of millions of yuan in the first round of financing, and the investor was Yuansheng capital. This round of financing will be mainly used to deepen platform technology, promote pipeline projects and expand talent team.
Yuanyi wisdom is a biotechnology company focusing on the seamless integration of artificial intelligence and experimental technology. In view of the unmet clinical needs and the technical challenges of target identification and molecular design in new drug R & D, Yuanyi wisdom realizes efficient target mechanism analysis, accurate drug molecular design and whole process optimization of R & D strategy through multi-disciplinary and integrated artificial intelligence technology, so as to break through the bottleneck of traditional R & D mode and find better drug molecules. At present, Yuanyi wisdom is the only computing platform with 10 billion level virtual screening capability of multiple molecular forms, and has the early R & D capability of small molecules and biological drugs at the same time. It is reported that in addition to self-developed pipelines, Yuanyi wisdom has also launched a number of cooperative pipeline projects with domestic and foreign pharmaceutical enterprises.
Pan Lurong, founder and CEO of Yuanyi wisdom, said, "Yuanyi intelligence is in a leading position in the industry in the fields of molecular virtual screening, scientific informatics and molecular generation model. We have broken away from the traditional cro service mode of computing technology and enabled drug research and development with our own IP internal pipeline and independent encrypted AI software platform. Our AI platform will realize the industrial upgrading from 'computing tool' to real AI intelligent system."
This text is a result of machine translation.